Futuro del CRPC. Visión 360º

5 / 28

Local
Therapy
Androgen
Deprivation
Abiraterone
Docetaxel
Tumour burden
Time
NATURAL HISTORY OF PROSTATE CANCER
Hormono-sensitive Castrate-Resistant
Death
Asymptomatic Symptomatic
Metastatic disease